Xinnate AB

Xinnate AB develops proprietary peptides for prevention and treatment of wound and topical applications. The lead candidate TCP-25 is part of nature´s own host defense, and the focus is to utilize it’s proven anti-endotoxic properties in functionalized biomaterials and new wound formulations.